Recommendations for prophylaxis of venous thromboembolism: International Consensus and the American College of Chest Physicians fifth Consensus Conference on antithrombotic therapy

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 4, 2000, Pages 314-320

  Haas, Sylvia ^a  

^a Lehrst F Experimentelle O   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0033913289     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200007000-00011     Document Type: Review

References (20)

1. 1 McIntyre K: Medicolegal implications of consensus statements. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995, 108 (suppl):502S-505S.
2. 2 First ACCP-NHLBI National Conference on Antithrombotic Therapy. Chest 1986, 89(suppl):1S-106S.
3. 3 European Consensus Statement on the prevention of venous thromboembolism. Int Angiol 1992, 11:151-159.
4. 4 Nicolaides AN, Bergqvist D, Hull R: Prevention of venous thromboembolism. International Consensus Statement (Guideline according to scientific evidence). Int Angiol 1997, 16:3-38.
5. 5 Clagett GP, Anderson FA, Heit J, et al.: Prevention of venous thromboembolism. Chest 1995, 108:312S-334S.
6. 6 Clagett GP, Anderson FA, Geerts W, et al.: Prevention of venous thromboembolism. Chest 1998, 114:531S-560S.
7. 7 Verstraete M, Prentice CRM, Samama M, Verhaeghe R, on behalf of a European Working group: A European view on the North American Fifth Consensus on Antithrombotic Therapy Chest 2000, in press.
8. 8 Goldhaber S: Venous thromboembolism prophylaxis in medical patients. Thromb Haemost 1999, 82 (suppl):899-901. This paper reviews the risk of venous thromboembolism in various medical patient populations and addresses the heterogeneity of study results with regard to VTE-prevention.
9. 9 Samama MM, Cohen AT, Damron JY, et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999, 341:793-800. This is the first placebo-controlled comparison of two different doses of low-molecular-weight heparin in medical patients. The results have provided evidence that risk-assessment in this patient population should urgently be modified and, if given, low molecular weight heparins should be administered in high-risk prophylactic doses.
10. 10 Kleber FX, Witt C, Flosbach CW, Koppenhagen K, Vogel G, and the Prince Study Group: Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease. Thromb Haemost 1999, 82 (suppl August 1999):Abstr 1552.
11. 11 Pineo GF, Hull RD: Prophylaxis of venous thromboembolism following orthopedic surgery: mechanical and pharmacologic approaches and the need for extended prophylaxis. Thromb Haemost 1999, 82 (suppl):918-924. This paper is the latest overview on prophylaxis of venous thromboembolism following orthopedic surgery. The authors reviewed the body of data in elective hip and knee surgery, hip fractures, major trauma, and arthroscopic surgery.
12. 12 Agnelli G: Prevention of venous thromboembolism after neurosurgery. Thromb Haemost 1999, 82 (suppl):925-930. This paper reviews the epidemiology of venous thromboembolism in neurosurgery and the results of clinical trials that have studied the prevalence of this complication in this clinical setting. This overview provides comprehensive information on the results of pharmacologic and mechanical modalities of venous thromboembolism prevention, and it addresses open questions to be answered by future trials.
13. 13 Hillbom M, Erila T, Flosbach CW, et al.: Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherothrombotic stroke. Thromb Haemost 1999, 82 (suppl August 1999):Abstr 177.
14. 14 Mismetti P, Laporte-Simitsidis S, Tardy B, et al.: Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins. A meta-analysis of randomised clinical trials. Thromb Haemost 2000, 83:14-19. This is the first meta-analysis comparing unfractionated heparin and low molecular weight heparins for prevention of venous thromboembolism in medical patients.
15. 15 Sarret M, Kher A, Toulemonde F: Prophylaxis of venous thromboembolism in general, oncological, gynecological and neurological surgery. In: Low Molecular Weight Heparin. Edited by Sarret M, Kher A, Toulemonde F. New York: Marcel Dekker, 1999:29-246. This reference gathers the most relevant clinical studies, reviews the different pharmacokinetic properties, and assesses the therapeutic efficacy of low molecular weight heparins from 1985 to the present. The detailed compilation of study results offers a unique opportunity to form an impression of the strengths and the weaknesses of various compounds and dosing schedules.
16. 16 Guyatt GH, Cook DJ, Sackett DL, et al.: Grade of recommendation for antithrombotic agents. Chest 1998, 114:441S-444S.
17. 17 Haas SK, Wolf H, Encke A, Fareed J: Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin: a double blind comparison of certoparin and unfractionated heparin. Thromb Haemost 1999, 82 (suppl August 1999) :Abstr 1548.
18. 18 Fareed J, Haas S, Sasahara A (guest editors): Differentiation of low molecular weight heparins: Applied and Clinical Considerations. Semin Thromb Hemost 1999, 25 (suppl):1-147. This supplement summarizes all important issues of LMWH differentiation. The state of the art publications provide preclinical and clinical evidence on all issues related to LMWH individualization.
19. 19 Haas S, Turpie AGG (guest editors): From foundations to the future: building a new era in DVT management. Blood Coag Fibrinol 1999, 10 (suppl):S1-S131. Much of the work reported in this supplement discusses the development of risk assessment models for surgical and medical patients and takes into account both the clinical setting and patient-related factors.
20. 20 Hull RD, Brant RF, Pineo GF, et al.: Preoperative versus postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999, 159:137-141. This is the first meta-analysis comparing preoperative and postoperative initiation of LMWH prophylaxis in a high-risk patient population. The results of this analysis may be used for hypothesis regeneration in planning a prospective, randomized comparison of preoperative and postoperative initiation of pharmacologic prophylaxis.